Takeda Pharmaceutical Company Ltd (4502) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.
Takeda Pharmaceutical Company Ltd (4502) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.
Takeda Pharmaceutical Company Ltd (4502) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 13
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 14
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 15
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 16
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 17
Takeda Pharmaceutical Company Ltd, Medical Devices Deals, 2011 to YTD 2017 19
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 20
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deal Details 40
Asset Purchase 40
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 40
Venture Financing 40
Biomx Raises USD24 Million in Series A Venture Financing 40
Avidity Biosciences Raises USD10 Million in Series B Venture Financing 42
Cerevance Raises USD21.5 Million in Series A Financing 43
Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 43
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 44
Cortexyme Raises USD15 Million in Series A Financing Round 45
Univercells Raises USD3.4 Million in Equity Financing Round 46
Encycle Therapeutics Raises USD2 Million in Seed Financing 47
Presage Biosciences Raises Funds through Venture Financing 48
Naurex Raises USD80 Million in Series C Venture Financing 48
Naurex Raises US$25 Million In Venture Financing 50
VHsquared Secures Series A Funding Round 51
Hookipa Biotech Raises US$27 Million In Series B Financing 52
Heptares Therapeutics Raises US$21 Million In Series B Financing 54
Redwood Bioscience Raises US$8.6 Million In Venture Financing 55
Naurex Raises US$38 Million In Series B Financing 55
ArmaGen Technologies Raises US$17 Million In Series A Financing 57
Juventas Therapeutics Raises US$22.2 Million In Series B Venture Financing Round 58
LigoCyte Pharmaceuticals Raises US$2 Million In Venture Financing Round 60
Redwood Bioscience Secures Funding From Takeda Ventures 60
LigoCyte Pharma Secures US$5.5 Million In Venture Financing 61
Naurex Secures US$18 Million In Series A Financing Round 61
Fate Therapeutics Secures Venture Financing 62
CellCentric Raises Funds in Series B Financing Round 64
Private Equity 64
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 64
Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 65
Partnerships 66
Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 66
Takeda Pharma and Harrington Discovery Institute Enter into Partnership 67
Takeda Pharma Enters into Agreement with NuBiyota 67
PRA Health Sciences and Takeda Pharma Form Joint Venture 68
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 69
Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 70
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 71
Takeda Pharma Enters into Agreement with Maverick Therapeutics 72
Takeda Pharma and Ovid Therapeutics Enter into Agreement 73
Takeda Pharma Enters into Development Agreement wtih PvP Biologics 74
Arcturus Therapeutics Enters into Agreement with Takeda Pharma 75
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 75
EnGeneIC Enters into Agreement with Millennium Pharma 76
Takeda Pharma Enters into Agreement with Affilogic 77
Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 78
PRA Health Sciences Enters into Agreement with Takeda Pharma 78
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 79
Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 80
Takeda Pharma to Enter into Agreement with Altos Therapeutics 81
Exosome Diagnostics Enters into Agreement with Takeda Pharma 82
TB Alliance and Takeda Pharma Enter into Agreement 83
Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 83
Ariad Pharma Enters into Distribution Agreement with Biologix 84
Takeda Pharma Enters into Agreement with M2Gen 85
Takeda Pharma Forms Joint Venture with Roivant Sciences 86
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 87
Prosetta Biosciences Enters into Agreement with Takeda Pharma 88
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 89
Teva Pharma and Takeda Pharma Form Joint Venture 90
Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 91
Mersana Therapeutics Enters into Agreement with Takeda 92
Broad Institute Genomic Services Partners with Takeda Pharma 93
Takeda Pharma Enters into Partnership with enGene 94
Takeda Pharma Enters into Research Agreement with NsGene 95
Takeda Pharma Enters into Agreement with Enterome Bioscience 95
Vipergen Enters into Agreement with Takeda Pharma 96
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 97
Takeda Pharma Enters into R&D Agreement with Cour Pharma 97
University College London Enters into Research Agreement with Takeda Pharma 98
Takeda Pharma Enters into Agreement with Nanotherapeutics 99
DNDi Enters into Agreement with Takeda Pharma 100
ARIAD Pharma Enters into Distribution Agreement with Paladin 101
Takeda Pharma Enters into Agreement with Sanford-Burnham 101
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 102
Ariad Pharma Enters into Distribution Agreement with GEN Ilac 103
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 104
CiRA Enters into Co-Development Agreement with Takeda Pharma 105
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 105
Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 106
Mersana Expands Co-Development Agreement with Takeda Pharma 107
Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 108
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 109
Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 110
Presage Biosciences Expands its Research Agreement with Takeda Pharma 111
GE Healthcare Enters into R&D Agreement with Takeda Pharma 112
GVK Biosciences Forms Joint Venture with Takeda Pharma 113
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 114
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 115
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 115
Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 117
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 117
Mersana Therapeutics Expands Agreement with Takeda Pharma 119
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 120
Takeda Enters into R&D Agreement with University College London 121
Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 122
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 123
Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 123
Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 124
Takeda Pharma Enters into Distribution Agreement with Taisho Pharma 125
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 126
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 127
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 128
Scripps Research Institute Expands Research Agreement With Takeda 128
Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 130
Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 131
Gladstone Enters into Research Agreement with Takeda Pharma 132
Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 132
Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 133
Takeda Pharma Enters Into Research Agreement With BC Cancer Agency 134
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 135
Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 136
Yokogawa Electric Enters Into Co-Marketing Agreement With Wako Pure Chemical Industries For CellVoyager CV7000 137
Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 138
Metabolon Enters Into Co-Development Agreement With Takeda Pharma 139
Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 140
Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 140
CIC bioGUNE Enters into Agreement with Millennium Pharma 141
Takeda Pharma Enters Into Research Agreement With Osaka University 142
Interprotein Enters Into Co-Development Agreement With Takeda Pharma 143
Nycomed Enters Into Co-Marketing Agreement With Orion For Easyhaler 144
Eli Lilly Enters Into Co-Marketing Agreement With Takeda Pharma For Evista 145
Cellectis Bioresearch Enters Into Distribution Agreement With Wako Pure Chemical 146
Nycomed Enters Into Co-Marketing Agreement With Almirall 147
Nycomed Enters Into Distribution Agreement With Almirall, Anika, Bionorica, CSL And Helsinn 148
Dimerix Enters Into Second Research Agreement With Takeda Cambridge 149
Takeda Pharma Enters Into Research Collaboration With Samyang 150
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 151
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 152
Ariad Pharma Plans To Enter Into Partnership Agreement For Ponatinib 153
ARIAD Announces Co-Promotion Agreement With Merck 153
KINAXO Biotechnologies Extends Its Collaboration With Takeda San Diego 154
Takeda Enters Into Co-Development Agreement With Covance 155
Takeda Enters Into Co-Development Agreement With Quintiles 156
Pfizer Japan Enters Into Co-Promotion Agreement With Takeda Pharma 157
Pfizer Japan Extends Co-Promotion Agreement With Takeda Pharma 158
Evotec Enters Into Collaboration With Takeda Cambridge 159
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 160
Licensing Agreements 161
Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 161
Takeda Pharma Enters into Licensing Agreement with Exelixis 162
Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 163
Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 164
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 165
Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 166
Takeda Pharma Enters into Licensing Agreement with Crescendo Biologics 167
Dermira Enters into Option Agreement with Takeda Pharma 168
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 169
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 169
Incyte Enters into Licensing Agreement with ARIAD Pharma 170
Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 171
Takeda Pharma Enters into Licensing Agreement with Gencia 172
Takeda Pharma Enters into Licensing Agreement with Kaketsuken 173
Takeda Enters into Licensing Agreement with ImmunoGen 174
Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 175
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 175
Mersana Exercises Option for License Agreement with Millennium 176
Sucampo Pharma Expands Licensing Agreement with Takeda Pharma 177
Ariad Pharma Amends Licensing Agreement with Bellicum Pharma 179
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 180
Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 181
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 182
Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 183
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 184
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 186
Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 187
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 188
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 189
Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 190
Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 191
Nycomed Enters Into Licensing Agreement With Almirall For Ebastine 192
Nycomed Enters Into Licensing Agreement With Norgine For MOVIPREP 193
Nycomed Enters Into Licensing Agreement With Orion For Easyhaler 194
Takeda Expands Licensing Agreement With Genedata For Proteomics And Metabolomics Experiments 195
Nycomed Enters Into Licensing Agreement With F. Hoffmann-La Roche For Bonviva 196
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 197
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 198
ARIAD Pharma Expands Licensing Agreement With Bellicum Pharma 199
ARIAD Pharma Enters Into Licensing Agreement With ReGenX Biosciences 200
Millennium Enters Into Licensing Agreement With Sunesis Pharma 201
Dainippon Sumitomo Enters Into Licensing Agreement With Takeda For Ceftaroline Fosamil 202
Seattle Genetics Extends Licensing Agreement With Millennium 203
DURECT Amends Licensing Agreement With Nycomed 204
Eurand Enters Into Licensing Agreement With Nycomed For ZENPEP 206
Equity Offering 207
TiGenix to Raise USD10.4 Million in Private Placement of Shares 207
Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 208
Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 209
Prosetta Biosciences Raises USD31 Million in Series D Private Placement 210
Ariad Pharma Completes Public Offering Of Common Stock For US$323 Million 211
ARIAD Pharma Completes Exercise Of Underwriters Over-Allotment Option For US$258 Million 212
Debt Offering 214
Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 214
Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For US$593.5 Million 215
Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For US$593.5 Million 216
Takeda Pharma Completes Private Placement Of Notes Due 2015 For US$1,500 Million 217
Takeda Pharma Completes Private Placement Of Notes Due 2017 For US$1,500 Million 218
Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For US$870 Million 219
Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For US$745 Million 220
Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For US$745 Million 221
Asset Transactions 222
Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 222
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 223
Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 224
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 225
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 227
Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 228
Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For US$65 Million 228
CSL Behring Acquires Tachosil from Takeda Nycomed 229
Acquisition 230
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 230
Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 232
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 233
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 235
Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 236
Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 237
AstraZeneca May Acquire Ariad Pharma 238
Takeda America Completes Acquisition Of Inviragen For US$250 Million 239
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 241
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 242
Takeda Pharma Invests US$5 Million In Advinus Therapeutics 244
Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To US$265 Million 245
Takeda America Completes Acquisition Of URL Pharma For US$800 Million 247
Takeda Completes Acquisition Of Intellikine For US$310 Million 248
Takeda Pharma Completes Acquisition Of Nycomed International For US$13,681 Million 250
Nycomed Completes Acquisition Of Laboratorios Farmacol 253
Takeda Pharma Acquires Remaining 25% Stake In Tianjin Takeda From Tianjin Lisheng 254
Takeda Pharmaceutical Company Ltd - Key Competitors 255
Key Employees 256
Locations And Subsidiaries 258
Head Office 258
Other Locations & Subsidiaries 258
Recent Developments 267
Strategy And Business Planning 267
Apr 03, 2017: Takeda Consumer Healthcare Company starts its business 267
Feb 20, 2017: Takeda Announces Further Details of Splitting off (Simple Absorption-type Split) of Japan Consumer Healthcare Business Unit 268
Dec 02, 2016: Cerevance Launched With New Technology, Drug Portfolio And $36M In Cash To Tackle Brain Diseases 270
Oct 31, 2016: Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept 271
Jun 07, 2016: Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Womens Health and Prostate Cancer 273
Mar 31, 2016: Takeda and Teva Establish Teva Takeda Yakuhin in Japan 274
Feb 03, 2016: Takeda Intends to Establish a Wholly Owned Subsidiary Operating in the Consumer Healthcare Business in Japan 275
Financial Announcements 276
May 10, 2017: Takeda reports FY2016 full year results and issues FY2017 guidance 276
Feb 01, 2017: Takeda reports Q3 FY2016 results and improves year-end outlook 277
Oct 28, 2016: Takeda Reports First Half FY2016 Results and Raises Full Year Profit Guidance 278
Jul 29, 2016: Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance 279
May 10, 2016: Takeda Reports Results for Fiscal Year 2015 (April 2015 -March 2016) and Forecast for Fiscal Year 2016 280
Feb 03, 2016: Takeda reports results for three quarters (April-December) of FY2015, Reaffirms management guidance for the full year 282
Research And Development 284
Jul 29, 2016: Takeda Refocuses Research & Development On Targeted Therapeutic Areas, Concentrating in Japan and the U.S. 284
Corporate Communications 285
Mar 30, 2017: Takeda Announces Ricardo Marek as New President of Emerging Markets Business Unit 285
May 12, 2016: Takeda Appoints New Chief Financial Officer, James Kehoe 286
Apr 28, 2016: Takeda Expands Its Help At Hand Patient Assistance Program in U.S.; Reaches Even More Eligible Patients in the U.S. 287
Government and Public Interest 288
Feb 08, 2017: Takeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology Research 288
Nov 11, 2016: Takeda and the New York Academy of Sciences to Honor Commitment to Innovation in Key Areas of Therapeutic Focus 289
Nov 02, 2016: Takeda Donates 1 billion yen as an exclusive partner to the United Nations Foundation for "Global Measles Vaccination for Children" Program 290
Product News 291
Aug 31, 2016: Takeda Launches Largest Pharmaceutical Company-Sponsored Global Observational Study of Its Kind in Multiple Myeloma 291
Jul 15, 2016: Norgines Partner Takeda Russia-CIS Launches MOVIPREP In Russia 292
06/14/2016: Pioglitazone Decreases Type 2 Diabetes Risk in Stroke Patients with Insulin Resistance 293
06/11/2016: EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Associations 76th Scientific Sessions and Published in Diabetes Care 295
02/17/2016: Diabetes drug may prevent recurring strokes 296
Jan 11, 2016: Advinus Therapeutics, a TATA Enterprise, Meets Milestone in Drug Discovery Alliance 297
Product Approvals 298
Sep 28, 2016: Takeda Obtains New Drug Application Approval for Inisync Combination Tablets for the Treatment of Type 2 Diabetes in Japan 298
Clinical Trials 299
Jun 06, 2016: Takeda to Present New Data at the American Diabetes Associations 76th Scientific Sessions 299
Other Significant Developments 301
Aug 26, 2016: Takeda Announces Bold, New Access to Medicines Strategy 301
Appendix 302
Methodology 302
About GlobalData 302
Contact Us 302
Disclaimer 302
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 14
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 15
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 16
Takeda Pharmaceutical Company Ltd, Deals By Therapy Area, 2011 to YTD 2017 17
Takeda Pharmaceutical Company Ltd, Medical Devices Deals, 2011 to YTD 2017 19
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 20
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 40
Biomx Raises USD24 Million in Series A Venture Financing 40
Avidity Biosciences Raises USD10 Million in Series B Venture Financing 42
Cerevance Raises USD21.5 Million in Series A Financing 43
Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 43
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 44
Cortexyme Raises USD15 Million in Series A Financing Round 45
Univercells Raises USD3.4 Million in Equity Financing Round 46
Encycle Therapeutics Raises USD2 Million in Seed Financing 47
Presage Biosciences Raises Funds through Venture Financing 48
Naurex Raises USD80 Million in Series C Venture Financing 48
Naurex Raises US$25 Million In Venture Financing 50
VHsquared Secures Series A Funding Round 51
Hookipa Biotech Raises US$27 Million In Series B Financing 52
Heptares Therapeutics Raises US$21 Million In Series B Financing 54
Redwood Bioscience Raises US$8.6 Million In Venture Financing 55
Naurex Raises US$38 Million In Series B Financing 55
ArmaGen Technologies Raises US$17 Million In Series A Financing 57
Juventas Therapeutics Raises US$22.2 Million In Series B Venture Financing Round 58
LigoCyte Pharmaceuticals Raises US$2 Million In Venture Financing Round 60
Redwood Bioscience Secures Funding From Takeda Ventures 60
LigoCyte Pharma Secures US$5.5 Million In Venture Financing 61
Naurex Secures US$18 Million In Series A Financing Round 61
Fate Therapeutics Secures Venture Financing 62
CellCentric Raises Funds in Series B Financing Round 64
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 64
Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 65
Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 66
Takeda Pharma and Harrington Discovery Institute Enter into Partnership 67
Takeda Pharma Enters into Agreement with NuBiyota 67
PRA Health Sciences and Takeda Pharma Form Joint Venture 68
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 69
Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 70
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 71
Takeda Pharma Enters into Agreement with Maverick Therapeutics 72
Takeda Pharma and Ovid Therapeutics Enter into Agreement 73
Takeda Pharma Enters into Development Agreement wtih PvP Biologics 74
Arcturus Therapeutics Enters into Agreement with Takeda Pharma 75
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 75
EnGeneIC Enters into Agreement with Millennium Pharma 76
Takeda Pharma Enters into Agreement with Affilogic 77
Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 78
PRA Health Sciences Enters into Agreement with Takeda Pharma 78
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 79
Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 80
Takeda Pharma to Enter into Agreement with Altos Therapeutics 81
Exosome Diagnostics Enters into Agreement with Takeda Pharma 82
TB Alliance and Takeda Pharma Enter into Agreement 83
Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 83
Ariad Pharma Enters into Distribution Agreement with Biologix 84
Takeda Pharma Enters into Agreement with M2Gen 85
Takeda Pharma Forms Joint Venture with Roivant Sciences 86
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 87
Prosetta Biosciences Enters into Agreement with Takeda Pharma 88
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 89
Teva Pharma and Takeda Pharma Form Joint Venture 90
Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 91
Mersana Therapeutics Enters into Agreement with Takeda 92
Broad Institute Genomic Services Partners with Takeda Pharma 93
Takeda Pharma Enters into Partnership with enGene 94
Takeda Pharma Enters into Research Agreement with NsGene 95
Takeda Pharma Enters into Agreement with Enterome Bioscience 95
Vipergen Enters into Agreement with Takeda Pharma 96
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 97
Takeda Pharma Enters into R&D Agreement with Cour Pharma 97
University College London Enters into Research Agreement with Takeda Pharma 98
Takeda Pharma Enters into Agreement with Nanotherapeutics 99
DNDi Enters into Agreement with Takeda Pharma 100
ARIAD Pharma Enters into Distribution Agreement with Paladin 101
Takeda Pharma Enters into Agreement with Sanford-Burnham 101
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 102
Ariad Pharma Enters into Distribution Agreement with GEN Ilac 103
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 104
CiRA Enters into Co-Development Agreement with Takeda Pharma 105
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 105
Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 106
Mersana Expands Co-Development Agreement with Takeda Pharma 107
Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 108
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 109
Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 110
Presage Biosciences Expands its Research Agreement with Takeda Pharma 111
GE Healthcare Enters into R&D Agreement with Takeda Pharma 112
GVK Biosciences Forms Joint Venture with Takeda Pharma 113
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 114
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 115
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 115
Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 117
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 117
Mersana Therapeutics Expands Agreement with Takeda Pharma 119
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 120
Takeda Enters into R&D Agreement with University College London 121
Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 122
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 123
Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 123
Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 124
Takeda Pharma Enters into Distribution Agreement with Taisho Pharma 125
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 126
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 127
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 128
Scripps Research Institute Expands Research Agreement With Takeda 128
Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 130
Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 131
Gladstone Enters into Research Agreement with Takeda Pharma 132
Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 132
Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 133
Takeda Pharma Enters Into Research Agreement With BC Cancer Agency 134
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 135
Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 136
Yokogawa Electric Enters Into Co-Marketing Agreement With Wako Pure Chemical Industries For CellVoyager CV7000 137
Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 138
Metabolon Enters Into Co-Development Agreement With Takeda Pharma 139
Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 140
Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 140
CIC bioGUNE Enters into Agreement with Millennium Pharma 141
Takeda Pharma Enters Into Research Agreement With Osaka University 142
Interprotein Enters Into Co-Development Agreement With Takeda Pharma 143
Nycomed Enters Into Co-Marketing Agreement With Orion For Easyhaler 144
Eli Lilly Enters Into Co-Marketing Agreement With Takeda Pharma For Evista 145
Cellectis Bioresearch Enters Into Distribution Agreement With Wako Pure Chemical 146
Nycomed Enters Into Co-Marketing Agreement With Almirall 147
Nycomed Enters Into Distribution Agreement With Almirall, Anika, Bionorica, CSL And Helsinn 148
Dimerix Enters Into Second Research Agreement With Takeda Cambridge 149
Takeda Pharma Enters Into Research Collaboration With Samyang 150
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 151
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 152
Ariad Pharma Plans To Enter Into Partnership Agreement For Ponatinib 153
ARIAD Announces Co-Promotion Agreement With Merck 153
KINAXO Biotechnologies Extends Its Collaboration With Takeda San Diego 154
Takeda Enters Into Co-Development Agreement With Covance 155
Takeda Enters Into Co-Development Agreement With Quintiles 156
Pfizer Japan Enters Into Co-Promotion Agreement With Takeda Pharma 157
Pfizer Japan Extends Co-Promotion Agreement With Takeda Pharma 158
Evotec Enters Into Collaboration With Takeda Cambridge 159
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 160
Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 161
Takeda Pharma Enters into Licensing Agreement with Exelixis 162
Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 163
Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 164
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 165
Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 166
Takeda Pharma Enters into Licensing Agreement with Crescendo Biologics 167
Dermira Enters into Option Agreement with Takeda Pharma 168
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 169
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 169
Incyte Enters into Licensing Agreement with ARIAD Pharma 170
Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 171
Takeda Pharma Enters into Licensing Agreement with Gencia 172
Takeda Pharma Enters into Licensing Agreement with Kaketsuken 173
Takeda Enters into Licensing Agreement with ImmunoGen 174
Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 175
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 175
Mersana Exercises Option for License Agreement with Millennium 176
Sucampo Pharma Expands Licensing Agreement with Takeda Pharma 177
Ariad Pharma Amends Licensing Agreement with Bellicum Pharma 179
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 180
Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 181
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 182
Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 183
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 184
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 186
Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 187
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 188
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 189
Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 190
Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 191
Nycomed Enters Into Licensing Agreement With Almirall For Ebastine 192
Nycomed Enters Into Licensing Agreement With Norgine For MOVIPREP 193
Nycomed Enters Into Licensing Agreement With Orion For Easyhaler 194
Takeda Expands Licensing Agreement With Genedata For Proteomics And Metabolomics Experiments 195
Nycomed Enters Into Licensing Agreement With F. Hoffmann-La Roche For Bonviva 196
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 197
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 198
ARIAD Pharma Expands Licensing Agreement With Bellicum Pharma 199
ARIAD Pharma Enters Into Licensing Agreement With ReGenX Biosciences 200
Millennium Enters Into Licensing Agreement With Sunesis Pharma 201
Dainippon Sumitomo Enters Into Licensing Agreement With Takeda For Ceftaroline Fosamil 202
Seattle Genetics Extends Licensing Agreement With Millennium 203
DURECT Amends Licensing Agreement With Nycomed 204
Eurand Enters Into Licensing Agreement With Nycomed For ZENPEP 206
TiGenix to Raise USD10.4 Million in Private Placement of Shares 207
Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 208
Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 209
Prosetta Biosciences Raises USD31 Million in Series D Private Placement 210
Ariad Pharma Completes Public Offering Of Common Stock For US$323 Million 211
ARIAD Pharma Completes Exercise Of Underwriters Over-Allotment Option For US$258 Million 212
Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 214
Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For US$593.5 Million 215
Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For US$593.5 Million 216
Takeda Pharma Completes Private Placement Of Notes Due 2015 For US$1,500 Million 217
Takeda Pharma Completes Private Placement Of Notes Due 2017 For US$1,500 Million 218
Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For US$870 Million 219
Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For US$745 Million 220
Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For US$745 Million 221
Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 222
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 223
Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 224
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 225
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 227
Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 228
Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For US$65 Million 228
CSL Behring Acquires Tachosil from Takeda Nycomed 229
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 230
Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 232
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 233
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 235
Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 236
Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 237
AstraZeneca May Acquire Ariad Pharma 238
Takeda America Completes Acquisition Of Inviragen For US$250 Million 239
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 241
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 242
Takeda Pharma Invests US$5 Million In Advinus Therapeutics 244
Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To US$265 Million 245
Takeda America Completes Acquisition Of URL Pharma For US$800 Million 247
Takeda Completes Acquisition Of Intellikine For US$310 Million 248
Takeda Pharma Completes Acquisition Of Nycomed International For US$13,681 Million 250
Nycomed Completes Acquisition Of Laboratorios Farmacol 253
Takeda Pharma Acquires Remaining 25% Stake In Tianjin Takeda From Tianjin Lisheng 254
Takeda Pharmaceutical Company Ltd, Key Competitors 255
Takeda Pharmaceutical Company Ltd, Key Employees 256
Takeda Pharmaceutical Company Ltd, Other Locations 258
Takeda Pharmaceutical Company Ltd, Subsidiaries 258
Burmeister & Wain Scandinavian Contractor A/S, Power, Deals By Year, 2011 to YTD 2017 22
Burmeister & Wain Scandinavian Contractor A/S, Power, Deals by Type, 2011 to YTD 2017 23
Table of Contents 2
List of Tables 8
List of Figures 13
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 14
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 15
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 16
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 17
Takeda Pharmaceutical Company Ltd, Medical Devices Deals, 2011 to YTD 2017 19
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 20
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deal Details 40
Asset Purchase 40
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 40
Venture Financing 40
Biomx Raises USD24 Million in Series A Venture Financing 40
Avidity Biosciences Raises USD10 Million in Series B Venture Financing 42
Cerevance Raises USD21.5 Million in Series A Financing 43
Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 43
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 44
Cortexyme Raises USD15 Million in Series A Financing Round 45
Univercells Raises USD3.4 Million in Equity Financing Round 46
Encycle Therapeutics Raises USD2 Million in Seed Financing 47
Presage Biosciences Raises Funds through Venture Financing 48
Naurex Raises USD80 Million in Series C Venture Financing 48
Naurex Raises US$25 Million In Venture Financing 50
VHsquared Secures Series A Funding Round 51
Hookipa Biotech Raises US$27 Million In Series B Financing 52
Heptares Therapeutics Raises US$21 Million In Series B Financing 54
Redwood Bioscience Raises US$8.6 Million In Venture Financing 55
Naurex Raises US$38 Million In Series B Financing 55
ArmaGen Technologies Raises US$17 Million In Series A Financing 57
Juventas Therapeutics Raises US$22.2 Million In Series B Venture Financing Round 58
LigoCyte Pharmaceuticals Raises US$2 Million In Venture Financing Round 60
Redwood Bioscience Secures Funding From Takeda Ventures 60
LigoCyte Pharma Secures US$5.5 Million In Venture Financing 61
Naurex Secures US$18 Million In Series A Financing Round 61
Fate Therapeutics Secures Venture Financing 62
CellCentric Raises Funds in Series B Financing Round 64
Private Equity 64
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 64
Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 65
Partnerships 66
Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 66
Takeda Pharma and Harrington Discovery Institute Enter into Partnership 67
Takeda Pharma Enters into Agreement with NuBiyota 67
PRA Health Sciences and Takeda Pharma Form Joint Venture 68
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 69
Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 70
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 71
Takeda Pharma Enters into Agreement with Maverick Therapeutics 72
Takeda Pharma and Ovid Therapeutics Enter into Agreement 73
Takeda Pharma Enters into Development Agreement wtih PvP Biologics 74
Arcturus Therapeutics Enters into Agreement with Takeda Pharma 75
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 75
EnGeneIC Enters into Agreement with Millennium Pharma 76
Takeda Pharma Enters into Agreement with Affilogic 77
Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 78
PRA Health Sciences Enters into Agreement with Takeda Pharma 78
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 79
Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 80
Takeda Pharma to Enter into Agreement with Altos Therapeutics 81
Exosome Diagnostics Enters into Agreement with Takeda Pharma 82
TB Alliance and Takeda Pharma Enter into Agreement 83
Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 83
Ariad Pharma Enters into Distribution Agreement with Biologix 84
Takeda Pharma Enters into Agreement with M2Gen 85
Takeda Pharma Forms Joint Venture with Roivant Sciences 86
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 87
Prosetta Biosciences Enters into Agreement with Takeda Pharma 88
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 89
Teva Pharma and Takeda Pharma Form Joint Venture 90
Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 91
Mersana Therapeutics Enters into Agreement with Takeda 92
Broad Institute Genomic Services Partners with Takeda Pharma 93
Takeda Pharma Enters into Partnership with enGene 94
Takeda Pharma Enters into Research Agreement with NsGene 95
Takeda Pharma Enters into Agreement with Enterome Bioscience 95
Vipergen Enters into Agreement with Takeda Pharma 96
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 97
Takeda Pharma Enters into R&D Agreement with Cour Pharma 97
University College London Enters into Research Agreement with Takeda Pharma 98
Takeda Pharma Enters into Agreement with Nanotherapeutics 99
DNDi Enters into Agreement with Takeda Pharma 100
ARIAD Pharma Enters into Distribution Agreement with Paladin 101
Takeda Pharma Enters into Agreement with Sanford-Burnham 101
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 102
Ariad Pharma Enters into Distribution Agreement with GEN Ilac 103
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 104
CiRA Enters into Co-Development Agreement with Takeda Pharma 105
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 105
Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 106
Mersana Expands Co-Development Agreement with Takeda Pharma 107
Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 108
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 109
Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 110
Presage Biosciences Expands its Research Agreement with Takeda Pharma 111
GE Healthcare Enters into R&D Agreement with Takeda Pharma 112
GVK Biosciences Forms Joint Venture with Takeda Pharma 113
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 114
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 115
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 115
Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 117
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 117
Mersana Therapeutics Expands Agreement with Takeda Pharma 119
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 120
Takeda Enters into R&D Agreement with University College London 121
Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 122
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 123
Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 123
Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 124
Takeda Pharma Enters into Distribution Agreement with Taisho Pharma 125
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 126
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 127
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 128
Scripps Research Institute Expands Research Agreement With Takeda 128
Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 130
Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 131
Gladstone Enters into Research Agreement with Takeda Pharma 132
Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 132
Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 133
Takeda Pharma Enters Into Research Agreement With BC Cancer Agency 134
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 135
Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 136
Yokogawa Electric Enters Into Co-Marketing Agreement With Wako Pure Chemical Industries For CellVoyager CV7000 137
Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 138
Metabolon Enters Into Co-Development Agreement With Takeda Pharma 139
Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 140
Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 140
CIC bioGUNE Enters into Agreement with Millennium Pharma 141
Takeda Pharma Enters Into Research Agreement With Osaka University 142
Interprotein Enters Into Co-Development Agreement With Takeda Pharma 143
Nycomed Enters Into Co-Marketing Agreement With Orion For Easyhaler 144
Eli Lilly Enters Into Co-Marketing Agreement With Takeda Pharma For Evista 145
Cellectis Bioresearch Enters Into Distribution Agreement With Wako Pure Chemical 146
Nycomed Enters Into Co-Marketing Agreement With Almirall 147
Nycomed Enters Into Distribution Agreement With Almirall, Anika, Bionorica, CSL And Helsinn 148
Dimerix Enters Into Second Research Agreement With Takeda Cambridge 149
Takeda Pharma Enters Into Research Collaboration With Samyang 150
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 151
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 152
Ariad Pharma Plans To Enter Into Partnership Agreement For Ponatinib 153
ARIAD Announces Co-Promotion Agreement With Merck 153
KINAXO Biotechnologies Extends Its Collaboration With Takeda San Diego 154
Takeda Enters Into Co-Development Agreement With Covance 155
Takeda Enters Into Co-Development Agreement With Quintiles 156
Pfizer Japan Enters Into Co-Promotion Agreement With Takeda Pharma 157
Pfizer Japan Extends Co-Promotion Agreement With Takeda Pharma 158
Evotec Enters Into Collaboration With Takeda Cambridge 159
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 160
Licensing Agreements 161
Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 161
Takeda Pharma Enters into Licensing Agreement with Exelixis 162
Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 163
Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 164
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 165
Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 166
Takeda Pharma Enters into Licensing Agreement with Crescendo Biologics 167
Dermira Enters into Option Agreement with Takeda Pharma 168
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 169
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 169
Incyte Enters into Licensing Agreement with ARIAD Pharma 170
Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 171
Takeda Pharma Enters into Licensing Agreement with Gencia 172
Takeda Pharma Enters into Licensing Agreement with Kaketsuken 173
Takeda Enters into Licensing Agreement with ImmunoGen 174
Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 175
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 175
Mersana Exercises Option for License Agreement with Millennium 176
Sucampo Pharma Expands Licensing Agreement with Takeda Pharma 177
Ariad Pharma Amends Licensing Agreement with Bellicum Pharma 179
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 180
Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 181
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 182
Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 183
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 184
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 186
Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 187
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 188
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 189
Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 190
Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 191
Nycomed Enters Into Licensing Agreement With Almirall For Ebastine 192
Nycomed Enters Into Licensing Agreement With Norgine For MOVIPREP 193
Nycomed Enters Into Licensing Agreement With Orion For Easyhaler 194
Takeda Expands Licensing Agreement With Genedata For Proteomics And Metabolomics Experiments 195
Nycomed Enters Into Licensing Agreement With F. Hoffmann-La Roche For Bonviva 196
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 197
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 198
ARIAD Pharma Expands Licensing Agreement With Bellicum Pharma 199
ARIAD Pharma Enters Into Licensing Agreement With ReGenX Biosciences 200
Millennium Enters Into Licensing Agreement With Sunesis Pharma 201
Dainippon Sumitomo Enters Into Licensing Agreement With Takeda For Ceftaroline Fosamil 202
Seattle Genetics Extends Licensing Agreement With Millennium 203
DURECT Amends Licensing Agreement With Nycomed 204
Eurand Enters Into Licensing Agreement With Nycomed For ZENPEP 206
Equity Offering 207
TiGenix to Raise USD10.4 Million in Private Placement of Shares 207
Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 208
Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 209
Prosetta Biosciences Raises USD31 Million in Series D Private Placement 210
Ariad Pharma Completes Public Offering Of Common Stock For US$323 Million 211
ARIAD Pharma Completes Exercise Of Underwriters Over-Allotment Option For US$258 Million 212
Debt Offering 214
Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 214
Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For US$593.5 Million 215
Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For US$593.5 Million 216
Takeda Pharma Completes Private Placement Of Notes Due 2015 For US$1,500 Million 217
Takeda Pharma Completes Private Placement Of Notes Due 2017 For US$1,500 Million 218
Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For US$870 Million 219
Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For US$745 Million 220
Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For US$745 Million 221
Asset Transactions 222
Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 222
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 223
Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 224
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 225
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 227
Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 228
Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For US$65 Million 228
CSL Behring Acquires Tachosil from Takeda Nycomed 229
Acquisition 230
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 230
Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 232
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 233
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 235
Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 236
Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 237
AstraZeneca May Acquire Ariad Pharma 238
Takeda America Completes Acquisition Of Inviragen For US$250 Million 239
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 241
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 242
Takeda Pharma Invests US$5 Million In Advinus Therapeutics 244
Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To US$265 Million 245
Takeda America Completes Acquisition Of URL Pharma For US$800 Million 247
Takeda Completes Acquisition Of Intellikine For US$310 Million 248
Takeda Pharma Completes Acquisition Of Nycomed International For US$13,681 Million 250
Nycomed Completes Acquisition Of Laboratorios Farmacol 253
Takeda Pharma Acquires Remaining 25% Stake In Tianjin Takeda From Tianjin Lisheng 254
Takeda Pharmaceutical Company Ltd - Key Competitors 255
Key Employees 256
Locations And Subsidiaries 258
Head Office 258
Other Locations & Subsidiaries 258
Recent Developments 267
Strategy And Business Planning 267
Apr 03, 2017: Takeda Consumer Healthcare Company starts its business 267
Feb 20, 2017: Takeda Announces Further Details of Splitting off (Simple Absorption-type Split) of Japan Consumer Healthcare Business Unit 268
Dec 02, 2016: Cerevance Launched With New Technology, Drug Portfolio And $36M In Cash To Tackle Brain Diseases 270
Oct 31, 2016: Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept 271
Jun 07, 2016: Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Womens Health and Prostate Cancer 273
Mar 31, 2016: Takeda and Teva Establish Teva Takeda Yakuhin in Japan 274
Feb 03, 2016: Takeda Intends to Establish a Wholly Owned Subsidiary Operating in the Consumer Healthcare Business in Japan 275
Financial Announcements 276
May 10, 2017: Takeda reports FY2016 full year results and issues FY2017 guidance 276
Feb 01, 2017: Takeda reports Q3 FY2016 results and improves year-end outlook 277
Oct 28, 2016: Takeda Reports First Half FY2016 Results and Raises Full Year Profit Guidance 278
Jul 29, 2016: Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management Guidance 279
May 10, 2016: Takeda Reports Results for Fiscal Year 2015 (April 2015 -March 2016) and Forecast for Fiscal Year 2016 280
Feb 03, 2016: Takeda reports results for three quarters (April-December) of FY2015, Reaffirms management guidance for the full year 282
Research And Development 284
Jul 29, 2016: Takeda Refocuses Research & Development On Targeted Therapeutic Areas, Concentrating in Japan and the U.S. 284
Corporate Communications 285
Mar 30, 2017: Takeda Announces Ricardo Marek as New President of Emerging Markets Business Unit 285
May 12, 2016: Takeda Appoints New Chief Financial Officer, James Kehoe 286
Apr 28, 2016: Takeda Expands Its Help At Hand Patient Assistance Program in U.S.; Reaches Even More Eligible Patients in the U.S. 287
Government and Public Interest 288
Feb 08, 2017: Takeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology Research 288
Nov 11, 2016: Takeda and the New York Academy of Sciences to Honor Commitment to Innovation in Key Areas of Therapeutic Focus 289
Nov 02, 2016: Takeda Donates 1 billion yen as an exclusive partner to the United Nations Foundation for "Global Measles Vaccination for Children" Program 290
Product News 291
Aug 31, 2016: Takeda Launches Largest Pharmaceutical Company-Sponsored Global Observational Study of Its Kind in Multiple Myeloma 291
Jul 15, 2016: Norgines Partner Takeda Russia-CIS Launches MOVIPREP In Russia 292
06/14/2016: Pioglitazone Decreases Type 2 Diabetes Risk in Stroke Patients with Insulin Resistance 293
06/11/2016: EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Associations 76th Scientific Sessions and Published in Diabetes Care 295
02/17/2016: Diabetes drug may prevent recurring strokes 296
Jan 11, 2016: Advinus Therapeutics, a TATA Enterprise, Meets Milestone in Drug Discovery Alliance 297
Product Approvals 298
Sep 28, 2016: Takeda Obtains New Drug Application Approval for Inisync Combination Tablets for the Treatment of Type 2 Diabetes in Japan 298
Clinical Trials 299
Jun 06, 2016: Takeda to Present New Data at the American Diabetes Associations 76th Scientific Sessions 299
Other Significant Developments 301
Aug 26, 2016: Takeda Announces Bold, New Access to Medicines Strategy 301
Appendix 302
Methodology 302
About GlobalData 302
Contact Us 302
Disclaimer 302
List Of Tables
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 14
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 15
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 16
Takeda Pharmaceutical Company Ltd, Deals By Therapy Area, 2011 to YTD 2017 17
Takeda Pharmaceutical Company Ltd, Medical Devices Deals, 2011 to YTD 2017 19
Takeda Pharmaceutical Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 20
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 40
Biomx Raises USD24 Million in Series A Venture Financing 40
Avidity Biosciences Raises USD10 Million in Series B Venture Financing 42
Cerevance Raises USD21.5 Million in Series A Financing 43
Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 43
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 44
Cortexyme Raises USD15 Million in Series A Financing Round 45
Univercells Raises USD3.4 Million in Equity Financing Round 46
Encycle Therapeutics Raises USD2 Million in Seed Financing 47
Presage Biosciences Raises Funds through Venture Financing 48
Naurex Raises USD80 Million in Series C Venture Financing 48
Naurex Raises US$25 Million In Venture Financing 50
VHsquared Secures Series A Funding Round 51
Hookipa Biotech Raises US$27 Million In Series B Financing 52
Heptares Therapeutics Raises US$21 Million In Series B Financing 54
Redwood Bioscience Raises US$8.6 Million In Venture Financing 55
Naurex Raises US$38 Million In Series B Financing 55
ArmaGen Technologies Raises US$17 Million In Series A Financing 57
Juventas Therapeutics Raises US$22.2 Million In Series B Venture Financing Round 58
LigoCyte Pharmaceuticals Raises US$2 Million In Venture Financing Round 60
Redwood Bioscience Secures Funding From Takeda Ventures 60
LigoCyte Pharma Secures US$5.5 Million In Venture Financing 61
Naurex Secures US$18 Million In Series A Financing Round 61
Fate Therapeutics Secures Venture Financing 62
CellCentric Raises Funds in Series B Financing Round 64
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 64
Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 65
Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 66
Takeda Pharma and Harrington Discovery Institute Enter into Partnership 67
Takeda Pharma Enters into Agreement with NuBiyota 67
PRA Health Sciences and Takeda Pharma Form Joint Venture 68
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 69
Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 70
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 71
Takeda Pharma Enters into Agreement with Maverick Therapeutics 72
Takeda Pharma and Ovid Therapeutics Enter into Agreement 73
Takeda Pharma Enters into Development Agreement wtih PvP Biologics 74
Arcturus Therapeutics Enters into Agreement with Takeda Pharma 75
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 75
EnGeneIC Enters into Agreement with Millennium Pharma 76
Takeda Pharma Enters into Agreement with Affilogic 77
Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 78
PRA Health Sciences Enters into Agreement with Takeda Pharma 78
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 79
Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 80
Takeda Pharma to Enter into Agreement with Altos Therapeutics 81
Exosome Diagnostics Enters into Agreement with Takeda Pharma 82
TB Alliance and Takeda Pharma Enter into Agreement 83
Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 83
Ariad Pharma Enters into Distribution Agreement with Biologix 84
Takeda Pharma Enters into Agreement with M2Gen 85
Takeda Pharma Forms Joint Venture with Roivant Sciences 86
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 87
Prosetta Biosciences Enters into Agreement with Takeda Pharma 88
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 89
Teva Pharma and Takeda Pharma Form Joint Venture 90
Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 91
Mersana Therapeutics Enters into Agreement with Takeda 92
Broad Institute Genomic Services Partners with Takeda Pharma 93
Takeda Pharma Enters into Partnership with enGene 94
Takeda Pharma Enters into Research Agreement with NsGene 95
Takeda Pharma Enters into Agreement with Enterome Bioscience 95
Vipergen Enters into Agreement with Takeda Pharma 96
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 97
Takeda Pharma Enters into R&D Agreement with Cour Pharma 97
University College London Enters into Research Agreement with Takeda Pharma 98
Takeda Pharma Enters into Agreement with Nanotherapeutics 99
DNDi Enters into Agreement with Takeda Pharma 100
ARIAD Pharma Enters into Distribution Agreement with Paladin 101
Takeda Pharma Enters into Agreement with Sanford-Burnham 101
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 102
Ariad Pharma Enters into Distribution Agreement with GEN Ilac 103
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 104
CiRA Enters into Co-Development Agreement with Takeda Pharma 105
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 105
Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 106
Mersana Expands Co-Development Agreement with Takeda Pharma 107
Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 108
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 109
Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 110
Presage Biosciences Expands its Research Agreement with Takeda Pharma 111
GE Healthcare Enters into R&D Agreement with Takeda Pharma 112
GVK Biosciences Forms Joint Venture with Takeda Pharma 113
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 114
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 115
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 115
Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 117
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 117
Mersana Therapeutics Expands Agreement with Takeda Pharma 119
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 120
Takeda Enters into R&D Agreement with University College London 121
Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 122
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 123
Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 123
Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 124
Takeda Pharma Enters into Distribution Agreement with Taisho Pharma 125
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 126
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 127
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 128
Scripps Research Institute Expands Research Agreement With Takeda 128
Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 130
Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 131
Gladstone Enters into Research Agreement with Takeda Pharma 132
Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 132
Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 133
Takeda Pharma Enters Into Research Agreement With BC Cancer Agency 134
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 135
Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 136
Yokogawa Electric Enters Into Co-Marketing Agreement With Wako Pure Chemical Industries For CellVoyager CV7000 137
Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 138
Metabolon Enters Into Co-Development Agreement With Takeda Pharma 139
Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 140
Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 140
CIC bioGUNE Enters into Agreement with Millennium Pharma 141
Takeda Pharma Enters Into Research Agreement With Osaka University 142
Interprotein Enters Into Co-Development Agreement With Takeda Pharma 143
Nycomed Enters Into Co-Marketing Agreement With Orion For Easyhaler 144
Eli Lilly Enters Into Co-Marketing Agreement With Takeda Pharma For Evista 145
Cellectis Bioresearch Enters Into Distribution Agreement With Wako Pure Chemical 146
Nycomed Enters Into Co-Marketing Agreement With Almirall 147
Nycomed Enters Into Distribution Agreement With Almirall, Anika, Bionorica, CSL And Helsinn 148
Dimerix Enters Into Second Research Agreement With Takeda Cambridge 149
Takeda Pharma Enters Into Research Collaboration With Samyang 150
Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma 151
Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 152
Ariad Pharma Plans To Enter Into Partnership Agreement For Ponatinib 153
ARIAD Announces Co-Promotion Agreement With Merck 153
KINAXO Biotechnologies Extends Its Collaboration With Takeda San Diego 154
Takeda Enters Into Co-Development Agreement With Covance 155
Takeda Enters Into Co-Development Agreement With Quintiles 156
Pfizer Japan Enters Into Co-Promotion Agreement With Takeda Pharma 157
Pfizer Japan Extends Co-Promotion Agreement With Takeda Pharma 158
Evotec Enters Into Collaboration With Takeda Cambridge 159
Takeda Pharma Enters Into Co-Development Agreement With Kyoto University 160
Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 161
Takeda Pharma Enters into Licensing Agreement with Exelixis 162
Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 163
Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 164
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 165
Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 166
Takeda Pharma Enters into Licensing Agreement with Crescendo Biologics 167
Dermira Enters into Option Agreement with Takeda Pharma 168
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 169
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 169
Incyte Enters into Licensing Agreement with ARIAD Pharma 170
Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 171
Takeda Pharma Enters into Licensing Agreement with Gencia 172
Takeda Pharma Enters into Licensing Agreement with Kaketsuken 173
Takeda Enters into Licensing Agreement with ImmunoGen 174
Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 175
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 175
Mersana Exercises Option for License Agreement with Millennium 176
Sucampo Pharma Expands Licensing Agreement with Takeda Pharma 177
Ariad Pharma Amends Licensing Agreement with Bellicum Pharma 179
Infinity Pharma Amends Licensing Agreement with Millennium Pharma 180
Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 181
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 182
Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 183
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 184
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 186
Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 187
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 188
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 189
Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 190
Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 191
Nycomed Enters Into Licensing Agreement With Almirall For Ebastine 192
Nycomed Enters Into Licensing Agreement With Norgine For MOVIPREP 193
Nycomed Enters Into Licensing Agreement With Orion For Easyhaler 194
Takeda Expands Licensing Agreement With Genedata For Proteomics And Metabolomics Experiments 195
Nycomed Enters Into Licensing Agreement With F. Hoffmann-La Roche For Bonviva 196
Paladin Labs Enters Into Licensing And Distribution Agreement With Takeda For Fomepizole 197
ARIAD Pharma Enters Into Licensing Agreement With Clontech Labs 198
ARIAD Pharma Expands Licensing Agreement With Bellicum Pharma 199
ARIAD Pharma Enters Into Licensing Agreement With ReGenX Biosciences 200
Millennium Enters Into Licensing Agreement With Sunesis Pharma 201
Dainippon Sumitomo Enters Into Licensing Agreement With Takeda For Ceftaroline Fosamil 202
Seattle Genetics Extends Licensing Agreement With Millennium 203
DURECT Amends Licensing Agreement With Nycomed 204
Eurand Enters Into Licensing Agreement With Nycomed For ZENPEP 206
TiGenix to Raise USD10.4 Million in Private Placement of Shares 207
Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 208
Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 209
Prosetta Biosciences Raises USD31 Million in Series D Private Placement 210
Ariad Pharma Completes Public Offering Of Common Stock For US$323 Million 211
ARIAD Pharma Completes Exercise Of Underwriters Over-Allotment Option For US$258 Million 212
Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 214
Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For US$593.5 Million 215
Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For US$593.5 Million 216
Takeda Pharma Completes Private Placement Of Notes Due 2015 For US$1,500 Million 217
Takeda Pharma Completes Private Placement Of Notes Due 2017 For US$1,500 Million 218
Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For US$870 Million 219
Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For US$745 Million 220
Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For US$745 Million 221
Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 222
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 223
Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 224
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 225
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 227
Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 228
Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For US$65 Million 228
CSL Behring Acquires Tachosil from Takeda Nycomed 229
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 230
Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 232
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 233
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 235
Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 236
Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 237
AstraZeneca May Acquire Ariad Pharma 238
Takeda America Completes Acquisition Of Inviragen For US$250 Million 239
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 241
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 242
Takeda Pharma Invests US$5 Million In Advinus Therapeutics 244
Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To US$265 Million 245
Takeda America Completes Acquisition Of URL Pharma For US$800 Million 247
Takeda Completes Acquisition Of Intellikine For US$310 Million 248
Takeda Pharma Completes Acquisition Of Nycomed International For US$13,681 Million 250
Nycomed Completes Acquisition Of Laboratorios Farmacol 253
Takeda Pharma Acquires Remaining 25% Stake In Tianjin Takeda From Tianjin Lisheng 254
Takeda Pharmaceutical Company Ltd, Key Competitors 255
Takeda Pharmaceutical Company Ltd, Key Employees 256
Takeda Pharmaceutical Company Ltd, Other Locations 258
Takeda Pharmaceutical Company Ltd, Subsidiaries 258
List Of Figures
Burmeister & Wain Scandinavian Contractor A/S, Power, Deals By Year, 2011 to YTD 2017 22
Burmeister & Wain Scandinavian Contractor A/S, Power, Deals by Type, 2011 to YTD 2017 23
RELATED REPORTS
Gastrointestinal Drugs Global Market Forecast To 2022 Including: Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals Covering: Takeda Pharmaceticals, Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc, Johnson & Johnson
The gastrointestinal drugs market consists of sales of gastrointestinal drugs and related services by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases. This industry
View ReportTakeda Cambridge Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Takeda Cambridge Ltd (TCB), formerly Paradigm Therapeutics Limited, a subsidiary of Takeda Pharmaceutical Company Ltd, pharmaceutical company that develops novel compounds addressing in various therapeutics areas. The company specializes in
View ReportTakeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review
Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review
View ReportTakeda Pharmaceutical Company Limited - Strategy, SWOT and Corporate Finance Report
Takeda Pharmaceutical Company Limited - Strategy, SWOT and Corporate Finance ReportTakeda Pharmaceutical Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information.
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
